- SG$605.28m
- SG$523.70m
- SG$78.18m
- 80
- 33
- 84
- 76
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.21 | ||
| Price to Tang. Book | 7.21 | ||
| Price to Free Cashflow | 21.31 | ||
| Price to Sales | 7.74 | ||
| EV to EBITDA | 13.55 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 47.08% | ||
| Return on Equity | 50.31% | ||
| Operating Margin | 48.28% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SG$m | 62.14 | 60.75 | 76.6 | 83.79 | 78.18 | n/a | n/a | 0.59% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -32.81 | -0.66 | +28.71 | +8.35 | +21.65 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
TalkMed Group Limited is a Singapore-based investment holding company. The Company provides medical oncology and palliative care healthcare services. Its segments include Oncology services and Cellular and gene therapy related products and services. The Oncology services segment comprises medical oncology services targeting various cancers, such as breast cancer, colon cancer, lung cancer, liver, biliary and pancreatic cancers, gastro-intestinal cancers, head and neck cancers, leukemia, hematology malignancies and brain cancer. It includes Parkway Cancer Centre and Thu Cuc International General Hospital. The Cellular and gene therapy related products and services segment includes the provision of goods and services related to cellular and gene therapy through its subsidiaries, CellVec Pte. Ltd. and BioCell Innovations Pte. Ltd. The Company, through the Parkway Cancer Centre (PCC)-vehicle, offers a support system to cater to the psychosocial needs of its patients and their families.
Directors
- S. Chandra Das NEC (80)
- Peng Tiam Ang CEO (61)
- Boon Yong Lee CFO
- Kei Siong Khoo COO (58)
- Heng Chong Lim SEC
- Anne Low SEC
- Leong Ching Ching NED (52)
- Ching Ching Leong NED (52)
- Jen Howe Lim NED (66)
- Teong Jin Lim NED (64)
- Yock Hian Dan NID (53)
- Yih Pin Sitoh NID (57)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 10th, 2013
- Public Since
- January 30th, 2014
- No. of Shareholders
- 841
- No. of Employees
- 53
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
Singapore Exchange Securities Trading Ltd- Shares in Issue
- 1,330,283,302
- Address
- 101 Thomson Road, #09-02 United Square, 307591
- Web
- https://www.talkmed.com.sg/
- Phone
- +65 62586918
- Auditors
- Ernst & Young LLP
Upcoming Events for 5G3
Half Year 2025 Talkmed Group Ltd Earnings Release
Similar to 5G3
Alliance Healthcare
Singapore Exchange Securities Trading Ltd
Aoxin Q & M Dental
Singapore Exchange Securities Trading Ltd
Asiamedic
Singapore Exchange Securities Trading Ltd
Asia Vets Holdings
Singapore Exchange Securities Trading Ltd
Beverly JCG
Singapore Exchange Securities Trading Ltd
FAQ
What is the TalkMed share price?
As of Today at 14:35 UTC, shares in TalkMed are trading at SG$0.46. This share price information is delayed by 15 minutes.
How has the TalkMed share price performed this year?
Shares in TalkMed last closed at SG$0.46 and the price had moved by +13.75% over the past 365 days. In terms of relative price strength the TalkMed share price has outperformed the FTSE Developed Asia Pacific Index by +5.05% over the past year.
What are the analyst and broker recommendations for TalkMed?
The overall consensus recommendation for TalkMed is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the TalkMed dividend yield?
The TalkMed dividend yield is 1.98% based on the trailing twelve month period.
Does TalkMed pay a dividend?
Last year, TalkMed paid a total dividend of SG$0.01, and it currently has a trailing dividend yield of 1.98%. We do not have any data on when TalkMed is to next pay dividends.
When does TalkMed next pay dividends?
We do not have data on when TalkMed is to next pay dividends. The historic dividend yield on TalkMed shares is currently 1.98%.
How do I buy TalkMed shares?
To buy shares in TalkMed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of TalkMed?
As of the previous close price of SG$0.46, shares in TalkMed had a market capitalisation of SG$605.28m.
Where are TalkMed shares listed?
Here are the trading details for TalkMed:
- Country of listing: Singapore
- Exchange: SES
- Ticker Symbol: 5G3
What kind of share is TalkMed?
Based on an overall assessment of its quality, value and momentum TalkMed is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a TalkMed share price forecast for 2025?
The analyst consensus target price for shares in TalkMed is SG$0.49. That is 7.69% above the last closing price of SG$0.46.
Analysts covering TalkMed currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the TalkMed share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like TalkMed. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -11.95%.
As of the last closing price of SG$0.46, shares in TalkMed were trading +5.29% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the TalkMed PE Ratio?
The TalkMed PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SG$0.46.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of TalkMed?
TalkMed's management team is headed by:
- S. Chandra Das - NEC
- Peng Tiam Ang - CEO
- Boon Yong Lee - CFO
- Kei Siong Khoo - COO
- Heng Chong Lim - SEC
- Anne Low - SEC
- Leong Ching Ching - NED
- Ching Ching Leong - NED
- Jen Howe Lim - NED
- Teong Jin Lim - NED
- Yock Hian Dan - NID
- Yih Pin Sitoh - NID